{"id":418533,"date":"2021-01-21T08:03:45","date_gmt":"2021-01-21T13:03:45","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=418533"},"modified":"2021-01-21T08:03:45","modified_gmt":"2021-01-21T13:03:45","slug":"aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/","title":{"rendered":"AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Company Plans to Offer Service through Channel Partners<\/em>\n      <\/p>\n<p align=\"justify\">Mountain View, CA, Jan.  21, 2021  (GLOBE NEWSWIRE) &#8212; via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JJn_P_Gl9XCYHkfQuxZscaZ3rE_afVJWMV5Ez7Uzx9aY12uL3aHvtOy0nhde1hollQ7o-ETwJC9Mcnin2tNW8Sqye1lVz1pB-bhMCDWEfMQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>NewMediaWire<\/u><\/a> &#8212; Aditx Therapeutics, Inc. (Aditxt) (the \u201cCompany\u201d) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the operational launch of the AditxtScore\u2122 Immune Monitoring Platform as of February 1<sup>st<\/sup>, 2021.<\/p>\n<p align=\"justify\">The initial application of the platform will be AditxtScore\u2122 for COVID-19 which has been designed to provide a more complete assessment of an individual\u2019s infection and immunity status with respect to the SARS-CoV-2 virus. Infection status will be determined by evaluating the presence or absence of the virus, and immunity status by measuring levels of antibodies against viral antigens and their ability to neutralize the virus. Aditxt will soon be expanding the panel to measure other components of the immune response such as cellular immunity.<\/p>\n<p align=\"justify\">AditxtScore\u2122 for COVID-19 will be available as a Lab Developed Test (LDT) and processed at the AditxtScore\u2122 Immune Monitoring Center, which will operate as a CLIA-certified reference lab for the Company\u2019s prospective channel partners, including labs and hospitals.<\/p>\n<p align=\"justify\">\u201cSince the start of the pandemic, the focus has been on infection status. Moving forward, we believe the need for monitoring the presence and durability of immunity will continue to grow.\u00a0 By assessing infection status together with immunity status, AditxtScore\u2122 for COVID-19 will be well positioned to address both needs.\u00a0 We\u2019re currently in discussions with labs, hospitals and other channel partners around the world interested in incorporating AditxtScore\u2122 into their offerings. By acting as a reference lab, prospective channel partners can rapidly deploy the service without the need for additional equipment or staffing on their part,\u201d stated Amro Albanna, Co-founder and CEO of Aditxt.<\/p>\n<p>\n        <strong>About Aditx Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Certain statements in this press release constitute \u201cforward-looking statements\u201d within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company\u2019s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company\u2019s ongoing and planned product development; the Company\u2019s intellectual property position; the Company\u2019s ability to develop commercial functions; expectations regarding product launch and revenue; the Company\u2019s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in the Company\u2019s prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company\u2019s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p align=\"justify\">\n        <strong>Contacts: <\/strong><\/p>\n<p>        <strong>Investor Relations<\/strong><br \/>\n        <br \/> Jeff Ramson<br \/>PCG Advisory<br \/>Chief Executive Officer<br \/>IR@aditxt.com <br \/> 646-863-6341<\/p>\n<p>\n        <strong>Public Relations<\/strong><br \/>\n        <br \/>Kevin Harrington<br \/>5W Public Relations<br \/>aditxt@5wpr.com<\/p>\n<p>www.aditxt.com <\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTI4NCMzOTM4NTc3IzUwMDA3Mjc5NA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ed0c550a-e961-4554-9390-493cffc329a5\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company Plans to Offer Service through Channel Partners Mountain View, CA, Jan. 21, 2021 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; Aditx Therapeutics, Inc. (Aditxt) (the \u201cCompany\u201d) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the operational launch of the AditxtScore\u2122 Immune Monitoring Platform as of February 1st, 2021. The initial application of the platform will be AditxtScore\u2122 for COVID-19 which has been designed to provide a more complete assessment of an individual\u2019s infection and immunity status with respect to the SARS-CoV-2 virus. Infection status will be determined by evaluating the presence or absence of the virus, and immunity status by measuring levels of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-418533","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company Plans to Offer Service through Channel Partners Mountain View, CA, Jan. 21, 2021 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; Aditx Therapeutics, Inc. (Aditxt) (the \u201cCompany\u201d) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the operational launch of the AditxtScore\u2122 Immune Monitoring Platform as of February 1st, 2021. The initial application of the platform will be AditxtScore\u2122 for COVID-19 which has been designed to provide a more complete assessment of an individual\u2019s infection and immunity status with respect to the SARS-CoV-2 virus. Infection status will be determined by evaluating the presence or absence of the virus, and immunity status by measuring levels of &hellip; Continue reading &quot;AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-21T13:03:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTI4NCMzOTM4NTc3IzUwMDA3Mjc5NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st\",\"datePublished\":\"2021-01-21T13:03:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/\"},\"wordCount\":629,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzOTI4NCMzOTM4NTc3IzUwMDA3Mjc5NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/\",\"name\":\"AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzOTI4NCMzOTM4NTc3IzUwMDA3Mjc5NA==\",\"datePublished\":\"2021-01-21T13:03:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzOTI4NCMzOTM4NTc3IzUwMDA3Mjc5NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzOTI4NCMzOTM4NTc3IzUwMDA3Mjc5NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/","og_locale":"en_US","og_type":"article","og_title":"AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st - Market Newsdesk","og_description":"Company Plans to Offer Service through Channel Partners Mountain View, CA, Jan. 21, 2021 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; Aditx Therapeutics, Inc. (Aditxt) (the \u201cCompany\u201d) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the operational launch of the AditxtScore\u2122 Immune Monitoring Platform as of February 1st, 2021. The initial application of the platform will be AditxtScore\u2122 for COVID-19 which has been designed to provide a more complete assessment of an individual\u2019s infection and immunity status with respect to the SARS-CoV-2 virus. Infection status will be determined by evaluating the presence or absence of the virus, and immunity status by measuring levels of &hellip; Continue reading \"AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-21T13:03:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTI4NCMzOTM4NTc3IzUwMDA3Mjc5NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st","datePublished":"2021-01-21T13:03:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/"},"wordCount":629,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTI4NCMzOTM4NTc3IzUwMDA3Mjc5NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/","name":"AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTI4NCMzOTM4NTc3IzUwMDA3Mjc5NA==","datePublished":"2021-01-21T13:03:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTI4NCMzOTM4NTc3IzUwMDA3Mjc5NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTI4NCMzOTM4NTc3IzUwMDA3Mjc5NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxtscore-immune-monitoring-service-will-be-operational-on-february-1st\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AditxtScore\u2122 Immune Monitoring Service Will be Operational on February 1st"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/418533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=418533"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/418533\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=418533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=418533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=418533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}